Trial Profile

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elasomeran (Primary) ; Tozinameran (Primary) ; Ocrelizumab
Indications COVID 2019 infections
Focus Pharmacodynamics
Acronyms VIOLA

Most Recent Events

07 Nov 2023 Status changed from active, no longer recruiting to completed.
28 Oct 2022 Results reporting antibody and cellular responses to mRNA COVID-19 vaccines over 24 weeks presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
04 Apr 2022 Planned End Date changed from 14 Oct 2022 to 14 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com